NOVARTIS
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2011-08-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 26
- Registration Number
- NCT00426218
- Locations
- 🇮🇹
Novartis Investigative site, Origgio, Italy
Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 480
- Registration Number
- NCT00425997
- Locations
- 🇺🇸
Sites in USA, East Hanover, New Jersey, United States
A Drug-drug Interaction Study of Oral 1250 mg of Vatalinib Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor in Healthy Sterile or Postmenopausal Female Volunteers
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 24
- Registration Number
- NCT00426452
Safety and Efficacy of Valsartan Plus Hydrochlorothiazide and Amlodipine in Hypertensive Patients
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2008-08-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 80
- Registration Number
- NCT00426478
- Locations
- 🇨🇳
National Taiwan University, Taipei, R.o.c, Taiwan
Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 274
- Registration Number
- NCT00424346
- Locations
- 🇪🇸
Novartis, Barcelona, Spain
🇺🇸Sun Valley Arthritis Center, Ltd, Peoria, Arizona, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Metabolism of a Single Dose of Licarbazepine
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 16
- Registration Number
- NCT00424671
- Locations
- 🇨🇿
Novartis Investigative site, Prague, Czech Republic
Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 34
- Registration Number
- NCT00424541
- Locations
- 🇯🇵
Novartis Investigative Site, Tokyo, Japan
Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00422552
- Locations
- 🇬🇧
Novartis Investigative site, Horsham, United Kingdom
Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and Effect of BAF312
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-01-15
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 63
- Registration Number
- NCT00422175
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Drug Interaction of SMC021 With Concomitant Antacid (Calcium Carbonate/Magnesium Hydroxide).
Phase 2
Completed
- Conditions
- First Posted Date
- 2007-01-12
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 38
- Registration Number
- NCT00421590
- Locations
- 🇩🇰
Novartis Investigative site, Copenhagen, Denmark
© Copyright 2024. All Rights Reserved by MedPath